RxDoctor Payments Data

William Nguyen

Family · Long Beach, CANPI 1689316523

Payments from drug & device makers

$2,792in general payments, 2019–2025

Across 127 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$487
  • Pfizer$289
  • Novo Nordisk$281
  • Novartis$255
  • AstraZeneca$210
  • Merck$190
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,792 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$34,351
Medicare patients
122
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$126,902
OzempicSemaglutide59$78,834
EliquisApixaban48$61,910
EntrestoSacubitril/Valsartan38$42,855
XareltoRivaroxaban23$27,528
JanuviaSitagliptin Phosphate33$24,864
TrulicityDulaglutide20$23,202
FarxigaDapagliflozin Propanediol14$17,318
VascepaIcosapent Ethyl33$14,963
Repatha PushtronexEvolocumab13$11,170
Icosapent Ethyl24$9,744
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,411
JanumetSitagliptin Phos/Metformin Hcl13$7,729
Atorvastatin Calcium235$4,695
Advair HfaFluticasone Propion/Salmeterol11$4,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$169$126,902110 claims
Novo NordiskOzempic$281$78,83459 claims
PfizerEliquis$289$61,91048 claims
NovartisEntresto$255$42,85538 claims
MerckJanuvia, Janumet$190$32,59346 claims
Lilly USA, LLCTrulicity$66$23,20220 claims
AstraZenecaFarxiga$210$17,31814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →